News Feed
OncoDaily Pulse
OncoGrants
OncoDaily TV
NewsLetter
Voices
Not To Miss
FDA Approvals
New Paper Alert
OncoDaily 100
Community
OncoDaily Magazine
Career Updates
Oncology Drugs
Dialogues
Stories

Celebrities and Cancer
Immune Oncology
Breast Oncology
Gastrointestinal Oncology
Lung Oncology
Hematology
Radiotherapy
Cancer Types
Science
Trial Updates
ASCO
ESMO
ESO
MASCC
Cancer Center Near Me
Oncologist Near Me
OncoDaily Party 2025

Childhood Cancer
Health Policy
Hall of Fame
OncoIndustry
Public Health
Oncology Tech
Blog Posts
BIGR
Global Cancer Movement
History
Oncolibrary
OncoThon 2025
Yvonne Award 2025

May / 2026

May 2026
M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

« Apr

OncoDaily IO OncoDaily GI Hemostasis Today Fertility News

Voices
Not To Miss
FDA Approvals
New Paper Alert
OncoDaily 100
Community
OncoDaily Magazine
Career Updates
Oncology Drugs
Dialogues
Stories

News Feed
OncoDaily Pulse
OncoGrants
OncoDaily TV
NewsLetter

How Do We Ensure the Progress is Not Only Achieved, But Shared - CancerWorld

How Do We Ensure the Progress is Not Only Achieved, But Shared - CancerWorld

25 Posts Not To Miss From WHA79

25 Posts Not To Miss From WHA79

How Desmond Yip Helped Build Cancer Care in the Solomon Islands

How Desmond Yip Helped Build Cancer Care in the Solomon Islands

Yvonne Awards 2026

Yvonne Awards 2026

OncoDaily Brings Sarcoma Experts Together at ASCO 2026

OncoDaily Brings Sarcoma Experts Together at ASCO 2026

Grand Rounds by OncoDaily: AI in Oncology Edition

Grand Rounds by OncoDaily: AI in Oncology Edition

BOT+BAL Demonstrates Durable Immune Benefit in Advanced Melanoma - Agenus

BOT+BAL Demonstrates Durable Immune Benefit in Advanced Melanoma - Agenus

Breaking the Undruggable: KRAS G12D Inhibition and the Emerging Era of Precision Oncology in PDAC

Breaking the Undruggable: KRAS G12D Inhibition and the Emerging Era of Precision Oncology in PDAC

Matthew Powell

Jul 20, 2024 10:54 pm

Blog Posts

David S. Miller: Why Cisplatin should not be added to radiotherapy for certain recurrent Endometrial Cancer

David S. Miller: Why Cisplatin should not be added to radiotherapy for certain recurrent Endometrial Cancer

Headlines

Dato-DXd Plus Durvalumab Shows Durable First-Line Activity in Advanced TNBC

The GI Cancers Alliance is Growing

Fabio Ynoe de Moraes: A Rejection is Not Always a Verdict on Quality

City Cancer Challenge (C/Can) and MSD Launch Global Partnership to Improve Women’s Cancer Care

Tedros Adhanom Ghebreyesus: Mike Ryan Received a Director-General's Award for Global Health

CancerWorld OncoDaily Medical Journal Hemostasis Today OncoDaily IO OncoDaily GI OncoDailyTV

OncoDaily™ | © 2023 - 2025

All rights reserved. Unauthorized reproduction, distribution, or transmission of any content on OncoDaily.com is strictly prohibited. For permission requests or inquiries, please contact OncoDaily directly. By accessing and using OncoDaily.com, you acknowledge and agree to comply with this copyright notice, as well as our Privacy Policy, Editorial Policy, Cookie Policy, and Disclaimer. Continued use of this website constitutes acceptance of all such terms and policies.

Phone number: +1 978 717 48 84

Email: info@oncodaily.com

About Privacy Policy Editorial Policy Cookie Policy Disclaimer

Crafted by Matemat

Oncology OncoDaily cancer Breast Cancer fight against cancer Global fight against cancer cancer care ASCO Lung cancer Cancer research Headlines ESMO immunotherapy NSCLC MD Anderson Cancer Center cancer treatment cancer awareness colorectal cancer Research ASCO24 Childhood Cancer clinical trials AACR FDA prostate cancer UICC Dana-Farber Cancer Institute American Cancer Society chemotherapy SIOP European Cancer Organisation Robert Orlowski Pancreatic Cancer Myeloma Paper of the Day NCI Myeloma American Society of Clinical Oncology Paolo Tarantino Vivek Subbiah National Cancer Institute AI radiation oncology cervical cancer WHO IASLC healthcare Memorial Sloan Kettering Cancer Center multiple myeloma Zainab Shinkafi-Bagudu bladder cancer

European School of Oncology

Sitemap

Hemostasis Today

Fertility News

Oncodaily Journal

Manage Cookie Consent

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options
Manage services
Manage {vendor_count} vendors
Read more about these purposes

View preferences

{title}
{title}
{title}

Manage Cookie Consent

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options
Manage services
Manage {vendor_count} vendors
Read more about these purposes

View preferences

{title}
{title}
{title}